Skip to main content

Advertisement

SpringerLink
Log in

Development and registration of chiral drugs

  • Reviews
  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

Abstract

In this review we describe the impact of chirality on drug development and registration in the United States, Japan and the European Community. Enantiomers may have differences in their pharmacological profiles, and, therefore, chiral drugs ask for special analytical and pharmacological attention during their development. However, the registration authorities have no clear policy towards the registration of chiral drugs. The absence of a clear policy regarding chirality causes a great deal of confusion and frustration at various levels and is not in the interest of industries developing newer and more beneficial drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allinger NL, Cava MP, De Jongh DC, Johnson CR, Lebel NA, Stevens CL. Organic chemistry. New York: Worth Publishers, 1976:98–101.

    Google Scholar 

  2. Cahn RS, Ingold CK, Prelog V. The specification of asymmetric configuration in organic chemistry. Experientia 1956; 12:81–94.

    Google Scholar 

  3. Ariëns EJ, Wuis EW, Veringa EJ. Stereoselectivity of bioactive xenobiotics. A pre-Pasteur attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology. Biochem Pharmacol 1988;37:9–18.

    PubMed  Google Scholar 

  4. Drayer DE. The early history of stereochemistry. In: Wainer IW, Drayer DE, eds. Drug stereochemistry: analytical methods and pharmacology. New York: Marcel Dekker, 1988:3–29.

    Google Scholar 

  5. Cushny AR. Atropine and the hyoscyamines. A study of the action of optical isomers. J Physiol 1904;30:176–94.

    Google Scholar 

  6. Powel JR, Ambre JJ, Ruo TI. The efficacy and toxicity of drug stereoisomers. In: Wainer IW, Drayer DE, eds. Drug stereochemistry: analytical methods and pharmacology. New York: Marcel Dekker, 1988:245–70.

    Google Scholar 

  7. Drayer DE. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin Pharmacol Ther 1986;40:125–33.

    PubMed  Google Scholar 

  8. Drayer DE. Pharmacokinetic differences between drug enantiomers in man. In: Wainer IW, Drayer DE, eds. Drug stereochemistry: analytical methods and pharmacology. New York: Marcel Dekker, 1988:209–25.

    Google Scholar 

  9. Ariëns EJ. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 1984, 26:663–8.

    PubMed  Google Scholar 

  10. Hyneck M, Dent J, Hook JB. Chirality: pharmacological action and drug development. In: Brown C, ed. Chirality in drug design and synthesis. San Diego: Academic Press, 1990:1–28.

    Google Scholar 

  11. Ariëns EJ. Racemic therapeutics. Problems all along the line. In: Brown C, ed. Chirality in drug design and synthesis. San Diego: Academic Press, 1990:29–43.

    Google Scholar 

  12. Davies SG. Chiral recognition in synthesis. In: Brown C, ed. Chirality in drug design and synthesis. San Diego: Academic Press, 1990:181–98.

    Google Scholar 

  13. Scott JW. Synthesis of enantiomerically pure drugs. In: Wainer IW, Drayer DE, eds. Drug stereochemistry: analytical methods and pharmacology. New York: Marcel Dekker, 1988:175–206.

    Google Scholar 

  14. Wozniak TJ, Bopp RJ, Jensen EC. Chiral drugs: an industrial analytical perspective. J Pharm Biomed Anal 1991;9:363–82.

    PubMed  Google Scholar 

  15. Souter RW, ed. Chromatographic separations of stereoisomers. Boca Raton: CRC Press, 1985:11–195.

    Google Scholar 

  16. Repta AJ, Baltezor MJ, Bansal PC. Utilization of an enantiomer as a solution to a pharmaceutical problem: application to solubilization of 1,2-di(4-piperazine-2,6-dione)propane. J Pharm Sci 1976;65:238–42.

    PubMed  Google Scholar 

  17. Kroemer HK, Turgeon J, Parker RA, Roden DM. Flecainide enantiomers. Disposition in human subjects and electro-physiologic actionsin vitro. Clin Pharmacol Ther 1989:46:584–90.

    PubMed  Google Scholar 

  18. Tobert JA, Cirillo VJ, Hitzenberg G, James I, Pryor J, Cook T, et al. Enhancement of the uricosuric properties of indacrinone by manipulation of the enantiomeric ratio. Clin Pharmacol Ther 1981;29:344–50.

    PubMed  Google Scholar 

  19. George CF, Fenyvesi C, Conolly ME, Dollery CT. Pharmacokinetics ofdextro, laevo and racemic propranolol in man. Eur J Clin Pharmacol 1972;4:74–6.

    PubMed  Google Scholar 

  20. Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Therap 1974; 15:424–30.

    Google Scholar 

  21. Giacomini KM, Nelson WL, Pershe RA, Valdivieso L, Turner-Tamiyasu K, Blaschke TF.In vivo interaction of the enantiomers of disopyramide in human subjects. J Pharmacokinet Biopharm 1986;14:335–56.

    PubMed  Google Scholar 

  22. Aso Y, Yoshioka S, Shibazaki T, Uchiyama M. The kinetics of the racemization of oxazepam in aqueuos solution. Chem Pharm Bull 1988;36:1834–40.

    PubMed  Google Scholar 

  23. Yang SK, Lu X-L. Racemization kinetics of enantiomeric oxazepams and stereoselective hydrolysis of enantiomeric oxazapam 3-acetate in rat liver microsomes and brain homogenate. J Pharm Sci 1989;78:789–95.

    PubMed  Google Scholar 

  24. Lambert WJ, Timmer PG. Racemization of itobutilide in solution. A factor to consider when choosing to develop the racemate or a single enantiomer. Pharm Res 1991;8:1444–7.

    PubMed  Google Scholar 

  25. Al-Badr AA, Muthadi FJ. Atropine, In: Florey K, ed. Analytical profiles of drug substances. Vol. 14. San Diego: Academic Press, 1985:325–89.

    Google Scholar 

  26. Beck WS, Geisslinger G, Engler H, Brune K. Pharmacokinetics of ibuprofen enantiomers in dogs. Chirality 1991;3:165–9.

    PubMed  Google Scholar 

  27. Chen C-S, Shieh W-R, Lu P-H, Harriman S, Chen C-Y. Metabolic stereoisomeric inversion of ibuprofen in mammals. Biochim Biophys Acta 1991;1078:411–7.

    PubMed  Google Scholar 

  28. Testa B. Some chemical and stereochemical aspects of diethylpropion metabolism in man. Acta Pharm Suec 1973; 10:441–54.

    PubMed  Google Scholar 

  29. Hutt AJ, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids, a novel route with pharmacological consequences. J Pharm Pharmacol 1983;35:693–704.

    PubMed  Google Scholar 

  30. Allen RC. To market, to market. In: Bailey DM, ed. Annual reports in medicinal chemistry. Vol. 19. San Diego: Academic Press, 1984:313–26.

    Google Scholar 

  31. Allen RC. To market, to market In: Bailey, DM, ed. Annual reports in medicinal chemistry. Vol. 20. San Diego: Academic Press, 1985:315–25.

    Google Scholar 

  32. Allen RC. To market, to market. In: Bailey DM, ed. Annual reports in medicinal chemistry. Vol. 21. San Diego: Academic Press, 1986:323–35.

    Google Scholar 

  33. Allen RC. To market, to market. In: Bailey DM, ed. Annual reports in medicinal chemistry. Vol. 22. San Diego: Academic Press, 1987:315–30.

    Google Scholar 

  34. Ong HH, Allen RC. To market, to market. In: Allen RC, ed. Annual reports in medicinal chemistry. Vol. 23. San Diego: Academic Press, 1988:325–48.

    Google Scholar 

  35. Ong HH, Allen RC. To market, to market. In: Allen RC, ed. Annual reports in medicinal chemistry. Vol. 24. San Diego: Academic Press, 1989:295–315.

    Google Scholar 

  36. Ong HH, Allen RC. To market, to market. In: Bristol JA, ed. Annual reports in medicinal chemistry. Vol. 25. San Diego: Academic Press, 1990:309–22.

    Google Scholar 

  37. Strupczewski JD, Ellis DB, Allen RC. To market, to market. In: Bristol JA, ed. Annual reports in medicinal chemistry. Vol. 26. San Diego: Academic Press, 1991:297–312.

    Google Scholar 

  38. Young JW. New technologies for industrial scale production of enantiomers. In: Second international conference on drug chirality. Strategies for successful decision making in the development of stereoisomeric drugs, 1991 Oct 28–29 [documentation]. London: IBC Technical Services, 1991.

    Google Scholar 

  39. Geneesmiddel Informatie Centrum KNMP. Informatorium Medicamentorum. The Hague: Royal Dutch Association for the Advancement of Pharmacy, 1991.

    Google Scholar 

  40. Holmes KD, Baum RG, Brenner GS, Eaton CR, Gross M, Grundfest CC, et al. Comments on enantiomerism in the drug development process. Pharm Technol 1990:46–52.

  41. Gross M. Development of chiral drugs in an evolving regulatory environment. Reg Affairs 1991;3:483–94.

    Google Scholar 

  42. De Camp WH. The FDA perspective on the development of stereoisomers. Chirality 1989;1:2–6.

    PubMed  Google Scholar 

  43. Kumkumian CS. The use of stereochemically pure pharmaceuticals. In: Wainer IW, Drayer DE, eds. Drug stereochemistry: analytical methods and pharmacology. New York: Marcel Dekker, 1988:299–311.

    Google Scholar 

  44. Gross M. Significance of drug stereochemistry in modern pharmaceutical research and development. In: Bristol JA, ed. Annual reports in medicinal chemistry. Vol. 25. San Diego: Academic Press, 1990;25:323–31.

    Google Scholar 

  45. Anonymous. Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances. Rockville: Center for drugs and biologics of the Food and Drug Administration, 1987.

  46. FDA's policy statement for the development of new stereoisomeric drugs. Chirality 1992;4:338–40.

    Google Scholar 

  47. Shindo H, Caldwell J. Regulatory aspects of the development of chiral drugs in apan: a status report. Chirality 1991;3:91–3.

    Google Scholar 

  48. The rules governing medicinal products in the European Community. Vol. II. Notice to Applicants for marketing authorizations for medicinal products for human use in the Member States of the European Community. Cat. Number CD-55-89-293-EN-C. Brussels: European Community, 1989.

  49. The rules governing medicinal products in the European Community. Vol. III. Guidelines on the quality, safety and efficacy of medicinal products for human use. Addendum July 1990. Cat. Number CB-55-89-843-EN-C. Brussels: European Community, 1990.

  50. Cartwright AC, The developing EC viewpoint. Strategies before and after 1993. In: Second international conference on drug chirality. Strategies for successful decision making in the development of stereoisomeric drugs, 1991 Oct 28–29 [documentation]. London: IBC Technical Services, 1991.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Analytical Chemistry and Toxicology, University Centre for Pharmacy, A. Deusinglaan 2, 9713, AW Groningen, the Netherlands

    Dirk T. Witte, Kees Ensing, Jan-Piet Franke & Rokus A. De Zeeuw

Authors
  1. Dirk T. Witte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kees Ensing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan-Piet Franke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rokus A. De Zeeuw
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Witte, D.T., Ensing, K., Franke, JP. et al. Development and registration of chiral drugs. Pharm World Sci 15 (Suppl 1), 10–16 (1993). https://doi.org/10.1007/BF02116164

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02116164

Keywords

Search

Navigation